| 1. |
|
|
| 2. |
- Grechnev, G. E., et al.
(författare)
-
Anisotropy of magnetic properties of Fe1+y Te
- 2014
-
Ingår i: Journal of Physics. - : IOP Publishing. - 0953-8984 .- 1361-648X. ; 26:43, s. 436003-
-
Tidskriftsartikel (refereegranskat)abstract
- The magnetic properties of Fe1+y Te single crystals (y similar or equal to 0.1 divided by 0.18) were studied at temperatures 4.2 divided by 300 K. At an ambient pressure, with decreasing temperature a drastic drop in chi(T) was confirmed at T similar or equal to 60 divided by 65 K, which appears to be closely related to the antiferromagnetic (AFM) ordering. It is found that the magnitudes of the anisotropy of magnetic susceptibility Delta chi. in the AFM phase are close in the studied samples, whereas the sign of the anisotropy apparently depends on the small variations of the excess iron y in Fe1+y Te samples. The performed DFT calculations of the electronic structure and magnetic properties for the stoichiometric FeTe compound indicate the presence of frustrated AFM ground states. There are very close energies and magnetic moments for the double stripe configurations, with the AFM axes oriented either on the basal plane or along the [0 0 1] direction. Presumably, both these configurations can be realized in Fe1+y Te single crystals, depending on the variations of the excess iron. This can provide different signs of magnetic anisotropy in the AFM phase, presently observed in the Fe1+y Te samples. For these types of AFM configuration, the calculations for the FeTe values of Delta chi are consistent with our experimental data.
|
|
| 3. |
- Baranovskiy, A. E., et al.
(författare)
-
Electronic structure, bulk and magnetic properties of MB6 and MB12 borides
- 2007
-
Ingår i: Journal of Alloys and Compounds. - : Elsevier BV. - 0925-8388 .- 1873-4669. ; 442:1-2, s. 228-230
-
Tidskriftsartikel (refereegranskat)abstract
- The bulk and magnetic properties of MB6 and MB12 were investigated on the basis of first principles electronic structure calculations. The elastic constants were measured for ZrB12, HoB12, ErB12, TmB12, LuB12, YB6 and LaB6 compounds at low temperatures. The calculated equations of states and balanced crystal orbital overlap populations have allowed to analyse bonding and magnetic properties of MB6 and MB12 .
|
|
| 4. |
- Dahl, O. E., et al.
(författare)
-
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty
- 2006
-
Ingår i: Pathophysiol Haemost Thromb. - : S. Karger AG. - 1424-8832. ; 35:6, s. 428-34
-
Tidskriftsartikel (refereegranskat)abstract
- In an analysis of the Melagatran Thrombosis Prophylaxis in Orthopedic Surgery (METHRO) III study, we evaluated whether concomitant administration of aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) with the direct thrombin inhibitor melagatran/ximelagatran or the low-molecular-weight heparin enoxaparin increased bleeding in patients undergoing major joint surgery. Further objectives were to compare the influence of the timing of initial postoperative administration of melagatran/ximelagatran on bleeding in orthopedic patients receiving ASA/NSAIDs and in comparison with the preoperative administration of enoxaparin. ASA or NSAIDs in conjunction with melagatran/ximelagatran or enoxaparin did not increase bleeding. Bleeding rates were not significantly different, irrespective of the timing of the initial postoperative dose of melagatran/ximelagatran (4-8 vs. 4-12 h) when compared with preoperative (12 h) administration of enoxaparin. Transfusion rates were significantly lower with administration of melagatran/ximelagatran compared with enoxaparin.
|
|
| 5. |
- Dahl, O. E., et al.
(författare)
-
Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery : Effects of Timing of First Dose and Risk Factors for Thromboembolism and Bleeding Complications on Efficacy and Safety
- 2005
-
Ingår i: Clin Drug Investig. - 1173-2563. ; 25:1, s. 65-77
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVES: To examine the influence of timing of postoperative initiation of subcutaneous melagatran followed by oral ximelagatran, and of risk factors for venous thromboembolism (VTE; including deep vein thrombosis [DVT] and pulmonary embolism [PE]) and bleeding complications, on the efficacy and safety of this regimen, compared with preoperative enoxaparin sodium, following total hip replacement (THR) or total knee replacement (TKR) surgery. DESIGN: Statistical analyses of efficacy and safety in subgroups of the METHRO III intention-to-treat population. MAIN OUTCOME MEASURES: Main efficacy outcome measures were major VTE (proximal DVT, PE or VTE-related death) and total VTE (distal or proximal DVT, fatal or non-fatal PE). The main safety outcome measures were blood transfusion, severe bleeding events, blood loss, bleeding-related adverse events and need for reoperation. RESULTS: In the combined THR and TKR population, melagatran initiated 4 - <8 hours postoperatively was non-inferior to enoxaparin sodium with respect to the risks of total VTE (absolute risk reduction [ARR] 0; 95% confidence interval [CI] -4.4, 4.4) and major VTE (ARR -0.63; 95% CI -2.94, 1.67). The rate of major VTE was unaffected by the different risk factors. In the combined THR and TKR population, blood transfusion requirements were lower with melagatran/ximelagatran than enoxaparin sodium (odds ratio 0.83; 95% CI 0.71, 0.96; p = 0.016). CONCLUSIONS: Melagatran/ximelagatran initiated 4 - <8 hours postoperatively provided a comparable level of protection against total and major VTE to preoperative enoxaparin sodium. Major VTE rates and safety were consistent across different patient subgroups. Subcutaneous melagatran followed by fixed-dose oral ximelagatran offers an alternative to the standard European low molecular-weight heparin regimen in a wide range of patients.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Olsson, Bertil, et al.
(författare)
-
Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
- 2010
-
Ingår i: Thrombosis and Haemostasis. - 0340-6245. ; 103:Jan 13, s. 604-612
-
Tidskriftsartikel (refereegranskat)abstract
- AZD0837 is an investigational oral anticoagulant which is converted to the active form, ARH067637, a selective direct thrombin inhibitor. The present study, a multicentre, randomised, parallel-group, dose-guiding study, assessed the safety and tolerability of an immediate-release formulation of AZD0837 compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in atrial fibrillation (AF) patients. Two hundred fifty AF patients with at least one additional risk factor for stroke were randomised to receive either immediate-release AZD0837 (150mg twice daily [bid] or 350mg bid, blinded treatment) or dose-adjusted warfarin (international normalised ratio 2.0-3.0, open treatment) for three months. The safety and tolerability of 150mg bid AZD0837 appeared to be as good as that of warfarin. Total bleeding events were six with 150mg bid AZD0837, 15 with 350mg bid AZD0837, and eight with warfarin. Alanine aminotransferase elevations (>3xupper limit of normal) were infrequent, without apparent differences between treatment groups. A numerically higher incidence of serious adverse events was observed with 350mg bid AZD0837 compared with 150mg bid, with six of 13 being cardiac related, all with different diagnoses. An increase in mean serum creatinine of approximately 10% was observed in both AZD0837 groups, which returned to baseline after completion of therapy. There were no strokes, transient ischaemic attacks or cerebral haemorrhages with any of the treatments. In conclusion, the safety and tolerability of 150mg bid immediate-release AZD0837 appeared to be as good as that of dose-adjusted warfarin. However, larger studies will be needed to define the safety profile of AZD0837.
|
|
| 9. |
|
|
